SCHEMBL25754559

SCHEMBL25754559

COc1ccc(NC(=O)c2ccc(Br)nc2F)cc1S(=O)(=O)Nc1c(C)cccc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.55
MEN1 O00255 7/20 0.55
LMNA P02545 6/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
GAA P10253 3/20 0.55
ALDH1A1 P00352 3/20 0.55
ALOX12 P18054 1/20 0.55
CRHBP P24387 1/20 0.55
CRHR2 Q13324 1/20 0.55
MAPT P10636 7/20 0.49
POLB P06746 2/20 0.49
HPGD P15428 3/20 0.48
HDAC1 Q13547 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
HTT P42858 1/20 0.42
PKM P14618 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MPI P34949 1/20 0.42
STAT3 P40763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23846533 0.82 LMNA (0.56) KMT2AMEN1LMNASMN1; SMN2GAA
SCHEMBL25754438 0.82 KMT2A (0.48) KMT2AMEN1LMNASMN1; SMN2GAA
SCHEMBL23846362 0.82 SMN1; SMN2 (0.57) KMT2AMEN1LMNASMN1; SMN2GAA
SCHEMBL25754476 0.81 MEN1 (0.50) KMT2AMEN1LMNASMN1; SMN2GAA
SCHEMBL23846987 0.80 KMT2A (0.56) KMT2AMEN1LMNASMN1; SMN2GAA
SCHEMBL25754533 0.80 KMT2A (0.53) KMT2AMEN1LMNASMN1; SMN2GAA
SCHEMBL25755336 0.80 STAT3 (0.40) KMT2AMEN1SMN1; SMN2MAPTPOLB
SCHEMBL25754571 0.80 SMN1; SMN2 (0.55) KMT2AMEN1LMNASMN1; SMN2GAA
SCHEMBL25754546 0.79 LMNA (0.52) KMT2AMEN1LMNASMN1; SMN2GAA
SCHEMBL23846327 0.79 KMT2A (0.53) KMT2AMEN1LMNASMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF AMATHUS THERAPEUTICS, INC. (US) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174523-A1 BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF TRAP1, PINK1, TP53BP1 KMT2A 4864/4885MEN1 3902/4885LMNA 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.